FORM PTO-1449

CK

OIPE 24 2003 CS

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. Serial No. 10/660128

Applicant

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Ashkenazi et al.

Filing Date 11 Sep 2003 Group 1646

U.S. PATENT DOCUMENTS

xaminer nitials			Document Number	Date	Name	Class	Subclass	Filing Date
CK	Г	1	2003/0036168	20.02.03	Ni et al.		/	
1		2	2003/0073187	17.04.03	Ni et al.			
1		3	2003/0108516	12.06.03	Ni et al.		/	
		4	2003/0133932	17.07.03	Zhou et al.			
		5	5,763,223	09.06.98	Wiley et al.	\		
	•	6	6,342,363 B1	29.01.02	Ni et al.		\wedge	
1/		7	6,429,186	06.08.02	Fuh et al.			
V	ŀ	8	6,433,147	13.08.02	J. Ni et al.			
CI		9	6,461,823	08.10.02	Ni et al.	/	\	

FOREIGN PATENT DOCUMENTS

Examiner nitials			Document Number	Date		Country	:	Class	Subclass	Transla Yes	ition No
	٠	10	WO 00/67793	16.11.00	PCT				,		
CK		11	WO 02/094880	28.11.02	PCT				/		
	-	12	WO 02/097033 .	05.12.02	PCT						
	l	13	WO 03/037913	08.05.03	PCT				/		
	l	14	WO 03/038043	08.05.03	PCT				/		
		15	WO 03/042367	22.05.03	PCT			\	/		
	*	16	WO 92/15698	17.09.92	PCT			\	/		•
	-	17	WO 97/01633	16.01.97	PCT		•)	1		
	٠	18	WO 97/25428	17.07.97	PCT			/	\		
	*	19	WO 98/32856	30.07.98	PCT			/			
1	*	20	WO 98/51793	19.11.98	PCT			/		İ	
1/	*	21	WO 99/37684	29.07.99	PCT			/			
V	*	22	WO 99/64461	16.12.99	PCT			/	\	1	
CK	*	23	02/079377	10.10.02	WO			/			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

(!K	* 24	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" Symposium on Programmed Cell Death (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
		* 25	Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40." <u>Nature.</u> 357(6373):80-82 (1992)
		* 26	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" Cell 61:1303-1313 (1990)
1	/		Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors" <u>Current Opinion in Cell Biology</u> 11(2):255-260 (1999)
	7		Ashkenazi A "Apontosis regulation by death and decoy recentors" FASER Tournal (Annual Meeting of the

* 28 American Societies for Experimental Biology on Biochemistry and Molecular Biology) 13(7):A1336 (1999)

Examiner Date Considered



PANFMAN!

U.S. Dept. of Commerce

Patent and Trademark Office

Serial No. Atty Docket No. 10/660128 P1245R1P2BC1 **Applicant**

LIST OF DISCLOSURES CITED BY APPLICANT

FORM PTO-1449

Ashkenazi et al.

	(U	lse sev	veral sheets if necessary)	Filing Date	Group				
	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)								
CK		* 29	Baldwin, A., "The NF-KB and IKB Proteins: New Discoveries and Insights" Ann. Rev. Immunol. 14:649-683						
	Banner et al., *Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFB Complex: * 30 Implications for TNF Receptor Activation* Cell 73:431-445 (1993)								
	Barr and Tomei, "Apoptosis and Its Role in Human Disease" Bio/Technology 12:487-493 (1994) * 31								
		* 32	Blake et al., "Metal binding properties of a monoclonal antibod complexes" <u>Journal of Biological Chemistry</u> 271(44):27677-27685	y directed toward met (Nov 1, 1996)	cal-chelate				
		* 33	Bodmer et al., "TRAMP, A Novel Apoptosis-Mediating Receptor wit Factor Receptor 1 and Fas(Apo-1/CD95)." Immunity, 6:79-88 (1997)		to Tumor Necrosis				
		* 34	Boldin et al., "Involvement of MACH, a Novel MORTI/FADD-Interac Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)	ting Protease, in Fas	s/APO-1- and TNF				
		* 35	Boldin et al., "Self-Association of the "Death Domains" of the and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" Jo (1995)						
		* 36	Brockhaus et al., "Identification of Two Types of Tumor Necrosi Monoclonal Antibodies." Proc. Natl. Acad. Sci. USA 87:3127-3131	(1990)	•				
		* 37	Brojatsch et al., "CAR1, A TNFR-Related Protein, Is a Cellular Leukosis-Sarcoma Viruses and Mediates Apoptosis." Cell. 87:845-	855 (1996)					
		* 38	Browning et al., "Lymphotoxin β, a Novel Member of the TNF Famil Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)	ly That Forms a Heter	omeric Complex with				
		39	Campbell, A., "General Properties and applications of monoclona Technology, The Netherlands: Elsevier Science Publishers B.V., Charles B.V.,	hapter 1, pps. 1-32 (1984)				
		* 40	Carter et al., "Humanization of an Anti-p185HER2 Antibody For Hu Sci. USA 89:4285-4289 (May 1992)						
		* 41	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR For Apoptosis and Activate the NF-KB Pathway" Immunity 7:821-830 (19		FADD-Dependent				
		+ 42	Chinnaiyan and Dixit, "The Cell-Death Machine" Current Biology						
	,	* 43	Chinnaiyan et al., "FADD, a novel death domain-containing prote: Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)						
		* 44	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Far Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271	:4961-4965 (1996)					
		* 45	Chinnaiyan et al., *Interaction of CED-4 with CED-3 and CED-9: A Science 275:1122-1126 (1997)						
		* 46	Chinnaiyan et al., "Signal Transduction by DR3, A Death Domain-CD95." Science. 274:990-992 (1996)						
Ψ	<u>'</u>	* 47	Chuntharapai et al., *The induction and blocking of apoptosis by Journal (Annual Meeting of the Professional Research Scientists (1999)	for Experimental Bio					
CK		+ 48	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" Ce	<u>11</u> 81:479-482 (1995)					
Exan	nine	7	Da	te Considered					

	B	
FORM PTO-1449	MADEMARKE	U.S. Dept. of Commerce
	27 Addition	Patent and Trademark Office

Atty Docket No. Serial No. P1245R1P2BC1 10/660128 **Applicant**

LIST	OF DI	SCLOSURES CITED BY APPLICANT	Applicant Ashkenazi et al.					
		veral sheets if necessary)	Filing Date Group					
,,	030 301		11 Sep 2003					
		OTHER DISCLOSURES (Including Author, Title, Date	e, Pertinent Pages, etc.)					
CK	+ 49	Craig et al., "The role of structure in antibody cross-reactiv <u>Journal of Molecular Biology</u> 281(1):183-201 (Aug 7, 1998)	ity between peptides	and folded proteins				
	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-y" European Journal of Immunology 17:689-693 (1987)							
	* 51	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" Journal of Experimental Medicine 186(7):1165-1170 (1997)						
	• 52	Enari et al., "Involvement of an ICE-like protease in Fas-medi	ated Apoptosis" <u>Natur</u>	<u>e</u> 375:78-81 (1995)				
	* 53	Engberg et al. Antibody Engineering Protocols pps. 375 (1995)						
	• 54	Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)						
	* 55	Goodwin et al., "Molecular Cloning and Expression of the Type Necrosis Factor." Mol. Cell. Bio. 11:3020-3026 (1991)	1 and Type 2 Murine R	eceptors for Tumor				
	* 56	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: In Lymphomas" <u>Blood</u> 85:3378-3404 (1995)	volvement in the Path	ology of Malignant				
CK	57	Gussow & Seemann, "Humanization of Monoclonal Antibodies" Meth. Enzymology, Academic Press, Inc. Vol. 203:99-121 (1991)						
	* 58	Gussow et al., "Humanization of Monoclonal Antibodies" Methods Antibodies 203:99-117 DUPLICATE	in Enzymology/Humani	zation of Monoclonal				
CK	* 59	Hale et al., "Demonstration of In Vitro and In Vivo Efficacy o TNF Receptors Expressed in E. coli." <u>J. Cell. Biochem.</u> (abstra						
CK	* 60	Hohmann et al., "Two different cell types have different major (TNFα)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1		tumor necrosis facto				
CK	* 61	Hsu et al., "TRADD-TRAP2 and TRADD-FADD interactions define tw transduction pathways" <u>Cell</u> 84:299-308 (1996)	o distinct TNF recept	or I signal				
C	K * 62	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Ce Apoptosis." <u>Cell.</u> 66:233-243 (1991)	ll Surface Antigen Fa	s Can Mediate				
	. 63	Janeway et al. <u>Immunobiology</u> , 3rd edition (1997)						
	* 63	Janeway et al. Immunobiology, Garland Press London and NY Vol.	Ath Edition 544 /100	71				
_	64	Concerns of all Amendmentology, Galland Fless Bondon and NI Vol.	Edition: 544 (155	.,				
· CK	* 65	Jo et al., "Apoptosis induced in normal human hepatocytes by t apoptosis-inducing ligand" <u>Nature Medicine</u> 6(5):564-567 (2000)	umor necrosis factor-	related				
CK	• 66	Johnson et al., "Expression and Structure of the Human NGF Receptor" Cell 47:545-554 (1986)						
CK	* 67	Kitson et al., "A Death-Domain-Containing Receptor that Mediate	es Apoptosis" <u>Nature</u>	384:372-375 (1996)				
CK	* 68	Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor." Proc. Natl. Acad. Sci. USA 87:8331-8335 (1990)						
xamine	er		Date Considered					

	10.5%
	ात २४ व्याव हो
•	TRANFMAN PO


U.S. Dept. of Commerce Patent and Trademark Office

Serial No. Atty Docket No. 10/660128 P1245R1P2BC1

FORM PTO-1449

		
Applicant		
Ashkenazi et al.		
Filing Date	Group	
11 Sep 2003		

LIST	T OF DI	SCLOSURES CITED BY APPLICANT	Ashkenazi et al.			
(Use sev	veral sheets if necessary)	Filing Date	Group		
			11 Sep 2003			
		OTHER DISCLOSURES (Including Author, Title, Date				
CF	₹ 69	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase ten-residue linkers form dimers and with zero-residue linker a (Apr 1997)	trimer* <u>Protein Engir</u>	neering 10(4):423-433		
	* 70			,		
	* 71	Lewis et al., "Cloning and Expression of cDNAs for Two Distinc Demonstrate One Receptor is Species Specific." PNAS USA, 88:28		s Factor Receptors		
	* 72	Loetscher et al., *Molecular Cloning and Expression of the Hum Cell 61:351-359 (1990)	an 55 kd Tumor Necrosi	s Factor Receptor"		
	+ 73	MacFarlane et al., "Identification and Molecular Cloning of Tw TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (19		the Cytotoxic Ligand		
	* 74	Mallett et al., "Characterization of the MRC OX40 Antigen of A Molecule Related to Nerve Growth Factor Receptor" EMBO Journal		T Lymphocytes - a		
	* 75	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a 7:1003-1006 (1997)	Truncated Death Domain	" Current Biology		
	* 76	Marsters et al., *Activation of Apoptosis by Apo-2 Ligand is In Current Biology. 6(6):750-752 (1996)	ndependent of FADD but	Blocked by CrmA."		
	* 77	Marsters et al., "Apo-3, A New Member of the Tumor Necrosis Fac Domain and Activates Apoptosis and NF-KB." <u>Curr. Biol.</u> 6(12):10		Contains a Death		
	* 78	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Family, Interacts with Members of the TNFR-Associated Factor Factors NF-KB and AP-1." J. Bio. Chem. 272(22):14029-14032 (1997)	amily and Activates th	e Transcription		
	* 79	Mongkolsapaya et al., "Cutting Edge: Lymphocyte Inhibitor of Ti Ligand): A New Receptor Protecting Lymphocytes From the Death 1 (1998)		_		
	* 80	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Med Receptor Family" <u>Cell</u> 87(3):427-436 (1996)	diated by a Novel Memb	er of the TNF/NGF		
	* 81	Moore et al., "Simultaneous measurement of cell cycle and apopt Chapter 15, 57:265-278 (1998)	totic cell death" <u>Meth</u>	ods in Cell Biology,		
	* 82	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Pr (Fas/APO-1) Death-Inducing Signaling Complex" Cell 85:817-827	-	to the CD95		
	* 83	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-14	456 (1995)			
	* 84	Nagata, S., "Apoptosis by Death Factor." <u>Cell.</u> 88:355-365 (Feb	1997)			
	* 85	Nophar et al., "Soluble Forms of Tumor Necrosis Factor Receptor TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble For Soluble Form of the Receptor." EMBO Journal, 9:3269-3278 (1990)	rm, Encodes Both the C			
	* 86	Pan et al., "An Antagonist Decoy Receptor and a Death-Domain Co 277:815-818 (Aug 1997)	ontaining Receptor for	TRAIL." <u>Science.</u>		
	* 87	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL." Scie	ence. 276:111-113 (Apr	4, 1997)		
CK	* 88	Peetre et al., "A tumor necrosis factor binding protein is pres Journal of Haematology 41:414-419 (1988)	sent in human biologic	al fluids" <u>European</u>		
Examine	er		Date Considered	 		



(230_	24	ZUU3
	E.		ني
	TON	PANF	AARK
•		PART	- 1002

U.S. Dept. of Commerce Patent and Trademark Office

Serial No. Atty Docket No. 10/660128 P1245R1P2BC1 **Applicant**

Li	ST OF	F DIS	SCLOSURES CITED BY APPLICANT	Ashkenazi et al.			
	(Use	e sevr	eral sheets if necessary)	Filing Date	Group		
	,-			11 Sep 2003			
			OTHER DISCLOSURES (Including Author, Title, Date,	·•			
CK			Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Me Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-1269		rosis Factor		
	1		Radeke et al., "Gene Transfer and Molecular Cloning of the Rat 325:593-597 (1987)	Nerve Growth Factor R	eceptor. Nature.		
	Ŀ	91	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u>				
	•	92	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Enc Interleukin-1β Converting Enzyme" Cell 69:597-604 (May 15, 1992	2)			
	Ŀ	93	Sachs et al., "Control of Programmed Cell Death in Normal and L Therapy" <u>Blood</u> 82:15-21 (1993)				
	1	94	Schall et al., "Molecular Cloning and Expression of a Receptor 61:361-370 (1990)	,			
	*	95	Schmid et al., *DNA Fragmentation: Manifestation of Target Cell Lines, Lymphotoxin-Secreting Helper T-cell Clones, and Cell-Fre PNAS USA. 83:1881-1885 (1986)	ee Lymphotoxin-Contain	ning Supernatant.		
	ŀ	96					
	•	97	Schneider et al., "TRAIL receptors 1 (DR4) and 2 (DR5) signal F. NF-KB" Immunity 7(6):831-836 (Dec 1997)				
	1	4	Screaton et al., "TRICK2, A New Alternatively Spliced Receptor TRAIL." Current Biology, 7:693-696 (1997)	that Transduces the C	ytotoxic Signal From		
	1.		Seckinger et al., *Purification and biologic characterization o Inhibitor* <u>Journal of Biological Chemistry</u> 264:11966-11973 (198	-	crosis factor α		
	+1		Sheridan et al., *Control of TRAIL-Induced Apoptosis by a Family Science 277:818-821 (1997)	y of Signaling and De	coy Receptors"		
	1.1		Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Invo Cell 89:309-319 (1997)	lved in the Regulation	n of Bone Density		
	*1		Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Proteins" <u>Science</u> 248:1019-1023 (1990)	Unusual Family of Cel	lular and Viral		
	1.1		Smith et al., "T2 Open Reading Frame From the Shope Fibroma Viri Receptor." <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)	us Encodes a Soluble)	Form of the TNF		
	1.1	104	Song et al., "Tumor Necrosis Factor-related Apoptosis-inducing l Autoimmune Inflammation and Cell Cycle Progression' <u>Journal of</u> (2000)	Experimental Medicine	191(7):1095-1103		
	1-1	105	Stamenkovic et al., "A B-Lymphocyte Activation Molecule Related Induced by Cytokines in Carcinomas." EMBO Journal, 8(5):1403-14	110 (1989)	•		
	•1	106	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u>	267:1445-1449 (1995)			
	/ 1-1		Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necros: Immunogenetics 37:199-203 (1993)	is Factor Receptors Ty	ype 1 and Type 2"		
Ċ	K • 1		Tartaglia et al., "A novel domain within the 55 kd TNF receptor (1993)	signals cell death (Cell 74(5):845-853		
Exami	Examiner Date Considered						
			•				

			TEO _	24	2003
FORM PTO-1449	,•	•	ATTO N	PANF	ARY PER
				·~ ·	

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. P1245R1P2BC1 Serial No. 10/660128

Applicant

LICTO	E DIS	SCLOSURES CITED BY APPLICANT	Applicant			
LIST U	Ashkenazi et al.					
(Use	e seve	eral sheets if necessary)	Filing Date	Group		
		OTHER DISCLOSURES (Including Author, Title, Dat	e, Pertinent Pages, etc.)			
CK .		Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus cri Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)				
1.	110	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet.</u> Develop. 6:39-44 (1996)				
1		Tewari et al., "Yama/CPP32B, a Mammalian Homolog of CED-3, Is the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-		otease That Cleaves		
1	112	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)				
1		Upton et al., "Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence." <u>Virology</u> . 184:370-382 (1991)				
	114	Upton et al., "Tumorigenic Poxviruses: Genomic Organization and DNA Sequence of the Telomeric Region the Shope Fibroma Virus Genome." <u>Virology</u> , 160:20-30 (1987)				
*	Verma et al., "Rel/NF-KB/IKB Family: Intimate Tales of Association and Dissociation" Genes Develop. 115 9:2723-2735 (1995)					
*	116	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Intera Receptor Superfamily" <u>Science</u> 278:138-141 (1997)	_			
*:	117	Walczak et al., "TRAIL-R2: A Novel Apoptosis-Mediating Receptor 16(17):5386-5397 (1997)	0.000			
*	118	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen Mediates Apoptosis" Nature 356:314-317 (1992)				
*:	119	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" Proc. Natl.Acad. Sci. USA 88:159-163 (1991)				
*:	120	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" Immunity 3:673-682 (1995)				
*:	121	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-N-terminal Kinase in T Cells." J. Bio. Chem. 272(40):25190-25194 (Oct 3, 1997)				
	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)					
.,	123	Yonehara et al., "A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor." <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)				
√ -:	124	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)				
CK +1		Zou et al., "Apaf-1, a Human Protein Homologous to C. elegans c-Dependent Activation of Caspase-3" <u>Cell</u> 90:405-413 (1997)	CED-4, Participates in	n Cytochrome		
				•		
xaminer		/Claire Kaufman/	Date Considered	6/2006		

/	OIPE WO
(g	AUG 1 5 2006
	TRADENIA PO

INFORMATION DISCLOSURE STATEMENT

Docket No.	22338-01016	Application No. 10/660,128
Applicant(s):	Avi ASHKENAZI et al.	Examiner: Kaufman, Claire M.
Filing Date:	September 11, 2003	Group Art Unit: 1646

U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	Name	Class	SUBCLASS	FILING DATE (IF APPROPRIATE)
-CK	6,943,020	Sep 13 2005	Ni et al.	-		
CK	7,060,272	Jun 13, 2006	Ni et al.			-
CV						
			1			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
i	DOCUMENT NO.	DATE	COUNTRY	CLASS	BUBCLASS	IRANSLATION
		I I .				
					1	[
	<u> </u>					
1		1 1				
		 			 	
	1	1				i
			- · - · · · · · · · · · · · · · · · · ·	 	 	
		1 1				[
	"				1	
1		1			.	ł
	Ĭ.					
	<u> </u>	1 1				1
		I				
	<u> </u>					ļ
ļ.	i	1 1				ŀ
		 			 	
i	,	1			1	
		 			+	
		1		1	1	Ì

	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent Pages, Etc.)
EXAMINER	/Claire Kaufman/	DATE CONSIDERED
		ion is in conformance with MPEP Section 609; ered. Include copy of this form with next communication to
Form PTO-SB/08	(modified)	SHEET 1 OF 1